BE-80-2100607

Trial medication for primary immune thrombocytopenia

18 - 50
  • Male
January - March
< 7 days
30
€ 5300

Are you:

  • a healthy male 
  • aged from 18 to 50 years (inclusive)
  • with a BMI from 18,0 to 30,0 kg/m² (inclusive)
  • non-smoker, (including e-cigarettes) or ex-smoker
  • not using daily medication

What does the trial involve?

SGS study BE-80-2100607  investigates the treatment of primary immune thrombocytopenia. 
During 18 weeks you will have the following appointments

  • a screening 
  • 2 periods of a 5-day (4-night) stay 
  • 14 to 15 short follow-up visits per period 
  • a final examination

Take part in this trial and:

  • help us develop tomorrow's medicines
  • and receive a generous tax-free (in Belgium) payment of € 5300

View information leaflet

Any other questions?

Ask your question 

BE-80-2100607

Registration form

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Any other questions?

Ask your question